Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocugen, Inc. - Common Stock (NQ:OCGN)

1.170 +0.140 (+13.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocugen, Inc. - Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
34 35 Next >
Why Is Ocugen (OCGN) Stock Up Today?
OCGN stock is getting a boost today on news that Ocugen is partnering with Washington University on its Covid-19 vaccine. 
Via InvestorPlace
Ocugen Inks US Development Pact For Its Intranasal COVID-19 Vaccine
Via Benzinga
So What's Happening With Ocugen Stock Today?
Ocugen Inc (NASDAQ: OCGN) shares are trading higher by 3.35% to $1.88 Wednesday morning after the company announced it entered into an exclusive license agreement with Washington University in St. 
Via Benzinga
Ocugen Announces Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-19 Vaccine in U.S., Europe, and Japan
From Ocugen
Via GlobeNewswire
Ford, Evotec And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
U.S. stock futures traded lower this morning after recording gains in the previous session. Here are some big stocks moving lower in today’s pre-market trading session. 
Via Benzinga
Where Ocugen Stands With Analysts
Analysts have provided the following ratings for Ocugen (NASDAQ:OCGN) within the last quarter: 
Via Benzinga
This COVID-19 Shot Stock Could Have Eye Disease Gene Therapy As Significant Driver, Mizuho Analyst Says
Via Benzinga
Ocugen's Partner COVID-19 Vaccine Covaxin Shows Encouraging Action In Children Below 18 Years
Via Benzinga
Why O2Micro International Is Trading Higher By 7%; Here Are 25 Stocks Moving Premarket
Gainers 
Via Benzinga
Why Ocugen Shares Are Diving
Ocugen Inc (NASDAQ: OCGN) shares are trading lower by 4.15% to $2.08 Monday morning. Shares of several vaccine companies at large are trading lower possibly after President Biden in a '60 Minutes'... 
Via Benzinga
MarketBeat: Week in Review 8/22 - 8/26
The markets are selling on news that interest rate hikes will continue past September. But here are some of the other stories for investors to follow this week 
Via MarketBeat
Topics Economy
Are Ocugen or Amarin Good Penny Stocks to Buy?
This article discusses the current state of Ocugen and Amarin, two penny stocks that highlight the risk and (potential) reward of penny stock investing. 
Via MarketBeat
Ocugen Diversifies Its Pipeline With New Cell Therapy Platform
Via Benzinga
OCGN Stock Falls Despite Positive FDA Update
Shares of the biotech company are falling despite news that the FDA has cleared it to resume clinical trials of its Covid-19 vaccine. 
Via InvestorPlace
FDA Removes Clinical Hold On Ocugen's COVID Vaccine Trial
Via Benzinga
Why PolyPid Dipped Over 73%; Here Are 60 Biggest Movers From Friday
Gainers Venus Concept Inc. (NASDAQ: VERO) jumped 54.9% to settle at $0.5419 on Friday. The company, last month, posted downbeat quarterly results. 
Via Benzinga
Indonesia Energy (INDO) Stock Soars as Natural Gas Prices Spike
Indonesia Energy (INDO) stock is rising higher on Tuesday alongside the increasing price of natural gas as Europe seeks new fuel sources. 
Via InvestorPlace
Why Is Ocugen (OCGN) Stock Climbing Higher Today?
Ocugen (OCGN) stock is gaining on Tuesday after Mizuho Securities analysts initiated coverage of the medical company's shares. 
Via InvestorPlace
The Top Reasons to Avoid the Ocugen Stock
WIth Ocugen, there’s nothing to get excited about here. Avoid the OCGN stock, as it heads significantly lower. 
Via InvestorPlace
Monitoring Board Gives Positive Recommendation On Ocugen's Eye Disease Gene Therapy Trial
Via Benzinga
Why Ocugen Shares Are Trading Higher Today
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 23, 2022
  
Via Benzinga
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Outlook For Ocugen
Ocugen (NASDAQ:OCGN) is set to give its latest quarterly earnings report on Friday, 2022-08-05. Here's what investors need to know before the announcement. Analysts estimate that Ocugen will report an... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Earnings Scheduled For August 5, 2022
Companies Reporting Before The Bell • Reservoir Media (NASDAQ:RSVR) is projected to report quarterly loss at $0.05 per share on revenue of $18.19 million. 
Via Benzinga
7 Stocks to Short Before July 2022
There are many highly overvalued publicly traded companies that will have trouble staying afloat, giving investors many stocks to short. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2022
Via Benzinga
Novavax Stock Could Give Back More of Its Pandemic-Era Gains
While trading at a very low multiple to the low end of earnings estimates, NVAX stock may still be trading at a premium. 
Via InvestorPlace
Earnings Scheduled For May 6, 2022
Companies Reporting Before The Bell • Brookfield Renewable (NYSE:BEP) is expected to report quarterly loss at $0.02 per share on revenue of $1.27 billion. 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.